Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, has announced positive outcomes from the dose escalation phase of its Phase 1/2 trial of GFH375, also known as VS-7375 in the United States. As reported, the trial, conducted by GenFleet Therapeutics, demonstrated an overall response rate $(ORR.AU)$ of 52% in patients with pancreatic ductal adenocarcinoma (PDAC) and 42% in those with non-small cell lung cancer (NSCLC) as of May 16, 2025. These results were disclosed during a rapid oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago. Verastem plans to commence a Phase 1/2a study of VS-7375 in the U.S. with potential global expansion, focusing on patients with advanced KRAS G12D mutant solid tumors. This study will assess the safety and efficacy of VS-7375, both as a standalone therapy and in combination with other treatments. The company announced this development and further details will be discussed during an investor webcast scheduled for June 2, 2025.